Cargando…

Safety of Off-Label Pharmacological Treatment in Pediatric Neuropsychiatric Disorders: A Global Perspective From an Observational Study at an Italian Third Level Children’s Hospital

Background: The acquisition of proper and relevant pediatric clinical data is essential to ensure tolerable and effective pediatric drug therapies. In the field of pharmacological treatment of neuropsychiatric disorders, the lack of sufficient high quality scientific evidence for pediatric age resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giurin, Maria Sole, Trojniak, Marta Paulina, Arbo, Anna, Carrozzi, Marco, Abbracciavento, Giuseppe, Monasta, Lorenzo, Zanus, Caterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039008/ https://www.ncbi.nlm.nih.gov/pubmed/35496268 http://dx.doi.org/10.3389/fphar.2022.837692

Ejemplares similares

High-school students and self-injurious thoughts and behaviours: clues of emotion dysregulation
por: Zanus, Caterina, et al.
Publicado: (2021)

Adolescent Admissions to Emergency Departments for Self-Injurious Thoughts and Behaviors
por: Zanus, Caterina, et al.
Publicado: (2017)

Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update
por: Asgharian, Parina, et al.
Publicado: (2022)

The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
por: Falzone, Luca, et al.
Publicado: (2018)

Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders
por: Bhattacharya, Anindya
Publicado: (2018)

Early diagnosis and Early Start Denver Model intervention in autism spectrum disorders delivered in an Italian Public Health System service
por: Devescovi, Raffaella, et al.
Publicado: (2016)

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Case report: A relevant misdiagnosis: Photosensitive epilepsy mimicking a blinking tic
por: Burlo, Francesca, et al.
Publicado: (2022)

A Two-Stage Screening Approach with I-TC and Q-CHAT to Identify Toddlers at Risk for Autism Spectrum Disorder within the Italian Public Health System
por: Devescovi, Raffaella, et al.
Publicado: (2020)

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
por: Verbaanderd, Ciska, et al.
Publicado: (2020)

Case Report: Off-label treatment of idiopathic hypereosinophilic syndrome with Omalizumab
por: Zhang, Zhiyu, et al.
Publicado: (2023)

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Prescription Pattern and Off-Label Use of Antipsychotics in a Middle Eastern Population
por: Bastaki, Kholoud, et al.
Publicado: (2021)

Selectivity and Specificity of Sphingosine 1-Phosphate Receptor Ligands: “Off-Targets” or Complex Pharmacology?
por: Pyne, Nigel J., et al.
Publicado: (2011)

Neuropsychiatric Disorders in Chronic Kidney Disease
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2019)

Off-label use of ivermectin for COVID-19: Are there any neuropsychiatric effects to be aware of?
por: O’Higgins, Marcelo G., et al.
Publicado: (2021)

Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline
por: Li, Guangyao, et al.
Publicado: (2022)

Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
por: Fischler, Pascal Valentin, et al.
Publicado: (2022)

Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use
por: Pesiou, Stella, et al.
Publicado: (2023)

The role of maternal obesity in the risk of neuropsychiatric disorders
por: Rivera, Heidi M., et al.
Publicado: (2015)

Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System
por: Gordon, Noa, et al.
Publicado: (2021)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
por: Ng, Kok Pin, et al.
Publicado: (2019)

The Submerged Dyslexia Iceberg: How Many School Children Are Not Diagnosed? Results from an Italian Study
por: Barbiero, Chiara, et al.
Publicado: (2012)

The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
por: Herrero Fernandez, Marta, et al.
Publicado: (2019)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study
por: Vitale, Antonio, et al.
Publicado: (2016)

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders
por: Scarante, Franciele F., et al.
Publicado: (2021)

Neuropsychiatric consequences of cardiovascular medications
por: Huffman, Jeff C., et al.
Publicado: (2007)

Editorial: Global excellence in inflammation pharmacology
por: Saha, Sukanya, et al.
Publicado: (2023)

Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study
por: Jiang, Qian, et al.
Publicado: (2020)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Gozzo, Lucia, et al.
Publicado: (2021)

Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors
por: Pin, Alessia, et al.
Publicado: (2020)

From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric Disorders
por: Romano, Adele, et al.
Publicado: (2016)

Dysfunctional mitochondrial processes contribute to energy perturbations in the brain and neuropsychiatric symptoms
por: Büttiker, Pascal, et al.
Publicado: (2023)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma)
por: Agrawal, Samir, et al.
Publicado: (2019)

Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System
por: Mascolo, Annamaria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mpq5alkgdqqfga9n9qkcjq8als